Clinical Trial Update: A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma [Phase 1]

View source ↗

Summary

This Phase I trial of OncoLAR, with or without Tamoxifen, in osteosarcoma patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• OncoLAR
• Tamoxifen (tamoxifen)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neoplasm Metastasis, Osteosarcoma | Phase 1 | Status: COMPLETED